Thursday, September 17, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Researchkisspeptinparkinsonsanimal-studyneuropeptides

Nasal kisspeptin-54 cuts alpha-synuclein in 6-OHDA rat Parkinson's model

Three weeks of daily intranasal dosing restored hippocampal CA1 synaptic plasticity and increased tyrosine hydroxylase-positive neuron survival, Turkish Journal of Medical Sciences reports.

PR
By Priya Raman · Science Reporter
Jun 18 20:00 ETSource: Turkish journal of medical sciences

The wire

  1. 01Sprague-Dawley rats lesioned with unilateral 6-OHDA into the medial forebrain bundle received daily nasal KP-54 or vehicle for three weeks starting three weeks post-lesion.
  2. 02Kisspeptin is tracked on the sexual-health and neuropeptide beat; this extends interest beyond reproductive signaling to a nasal delivery route and neurorestorative endpoints.
  3. 03Animal model only, with motor and cognitive testing by catalepsy, beam balance, Y-maze and object location; no human data and no dose translation reported.

From the source

Therapeutic potential of nasal kisspeptin-54 for reducing α-synuclein accumulation and restoring hippocampal synaptic plasticity in a 6-hydroxydopamine-induced rat model of Parkinson's disease

Turkish journal of medical sciences · 2026 · Gemici Sinen A, Savran E, Güleç OB et al.

Read at pubmed.ncbi.nlm.nih.gov
Source URL https://pubmed.ncbi.nlm.nih.gov/42676968/